Evotec Ag Stock Price, News & Analysis

Evotec SE announced a contract with the U.S. Department of Defense valued up to $49.9 million for the rapid development of monoclonal antibody drug prototypes targeting plague. Under this contract, Just - Evotec Biologics will advance mAb prototypes from initial discovery to Phase I clinical trials using its J.DESIGN platform, which integrates AI and machine learning. The goal is to produce effective medical countermeasures against plague, enhancing national security. The work will take place at Evotec's Redmond, Washington facility, part of the DOD's Advanced Development and Manufacturing network.

Evotec has begun construction of its J.POD ^® biologics manufacturing facility in Toulouse, France, expected to be operational in H2 2024. This facility will utilize advanced J.POD ^® technology to enhance clinical and commercial manufacturing capacity for biologics, addressing challenges in traditional manufacturing methods. The project is backed by funding from the French government and the Occitanie Region and is anticipated to create over 150 high-skill jobs in the area.

Evotec operates globally and focuses on the development of therapeutics across various medical areas.

Evotec SE has announced its acquisition of Central Glass Germany GmbH from Central Glass Co. Ltd., enhancing its drug substance manufacturing capabilities. The fully operational facility in Halle/Westphalia, with a team of ~60 chemists, is EU cGMP certified, covering over 5,000 square meters. This strategic move aligns with Evotec's commitment to rare diseases and precision medicine, aiming for earnings accretion by 2023/24. The contract, signed on August 24, 2022, was at a purchase price of €1, and the transaction is set to close on November 1, 2022.

Evotec SE and Alpine Immune Sciences have expanded their partnership to develop a commercial manufacturing process for ALPN-303, a dual BAFF/APRIL inhibitor. This collaboration builds on their ongoing first-in-human program initiated in 2020, with Evotec providing drug substance materials for clinical studies. The enhanced contract will utilize Evotec's J.DESIGN technology platform in Redmond, Washington, aiming to improve outcomes for patients with systemic lupus erythematosus and other autoimmune diseases.

Evotec SE will release its financial results for the first half of 2022 on August 11, 2022. A conference call will be held at 02:00 PM CEST to discuss the outcomes and company performance. Dial-in details are provided for various countries, and a webcast with presentation slides will also be available on their website. Evotec is a life science company focused on developing innovative therapeutics across multiple therapeutic areas, boasting over 200 proprietary projects in its pipeline.

Boehringer Ingelheim, Evotec, and bioMérieux have formed a joint venture named Aurobac Therapeutics SAS to combat Antimicrobial Resistance (AMR). Funded by Boehringer with 30 million EUR and 5 million EUR each from Evotec and bioMérieux, the venture aims to develop new antimicrobials and diagnostics. AMR poses a significant global health threat, with antibiotic-resistant infections causing around 1.27 million deaths annually. Aurobac seeks to implement precision medicine approaches and new economic models to enhance treatment strategies.

Evotec SE held its virtual Annual General Meeting (AGM) on June 22, 2022, with 65.68% of registered shareholders participating. All agenda items were adopted, including the election of Camilla Macapili Languille to the Supervisory Board, succeeding Kasim Kutay. The AGM approved the creation of Authorized Capital 2022 amounting to 20% of the share capital and a revised remuneration system for the Management Board, receiving 94.48% approval. The meeting also reaffirmed BDO AG as auditors for the fiscal year 2022.

Exscientia announced positive results from its Phase 1 healthy volunteer study of EXS-21546, a selective A_2A receptor antagonist. The study confirmed potency and selectivity with low CNS exposure, supporting a Phase 1b/2 study in patients with high adenosine signature solid tumors, anticipated to start in the second half of 2022. The trial showed dose-dependent effects and was well-tolerated, with only one serious adverse event recorded that resolved without intervention. These findings enhance the potential for EXS-21546 to improve immunomodulatory treatments in cancer therapy.

Evotec SE has announced a strategic drug discovery collaboration with Janssen Pharmaceutica NV to explore novel therapeutic candidates via its TargetAlloMod platform. This partnership aims for high-potential cell surface drug targets within various therapeutic areas. Besides research funding, Evotec stands to gain approximately €210 million per project in success-based milestones and tiered royalties on resultant products. The collaboration highlights Evotec's innovative strengths and commitment to delivering effective therapeutics.